The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...

Treatment with bleximenib and Venclexta (venetoclax) showed a tolerable safety profile in a phase 1b trial for patients with ...

Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed/refractory acute myeloid leukemia with mostly low-grade side effects.

Time and resilience have transformed the author's cancer experience into a fading memory, allowing life to return to normal.

Wendy Brooks, a patient with extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, sat down ...

The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...

Stage 4 metastatic breast cancer presents significant emotional and psychological challenges, requiring patients to adapt ...

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.

Recurrent or metastatic nasopharyngeal carcinoma is an aggressive disease, and long-term survival with chemotherapy alone is ...

The author cherishes family time during Thanksgiving and Christmas, despite undergoing cancer treatment. Chemotherapy and radiation therapy were completed during the 2018 holiday season, with minimal ...

Light the Night walk fosters community and remembrance for those affected by blood cancer, with symbolic lanterns for support ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.